Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1987 1
2009 1
2012 1
2014 1
2015 3
2016 4
2017 5
2018 3
2019 2
2020 3
2021 5
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Clinical and cost outcomes following genomics-informed treatment for advanced cancers.
Weymann D, Pollard S, Chan B, Titmuss E, Bohm A, Laskin J, Jones SJM, Pleasance E, Nelson J, Fok A, Lim H, Karsan A, Renouf DJ, Schrader KA, Sun S, Yip S, Schaeffer DF, Marra MA, Regier DA. Weymann D, et al. Cancer Med. 2021 Aug;10(15):5131-5140. doi: 10.1002/cam4.4076. Epub 2021 Jun 21. Cancer Med. 2021. PMID: 34152087 Free PMC article.
Postmarket policy considerations for biosimilar oncology drugs.
Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Renwick MJ, et al. Among authors: weymann d. Lancet Oncol. 2016 Jan;17(1):e31-8. doi: 10.1016/S1470-2045(15)00381-2. Epub 2015 Dec 23. Lancet Oncol. 2016. PMID: 26758759 Review.
Toward the diagnosis of rare childhood genetic diseases: what do parents value most?
Pollard S, Weymann D, Dunne J, Mayanloo F, Buckell J, Buchanan J, Wordsworth S, Friedman JM, Stockler-Ipsiroglu S, Dragojlovic N, Elliott AM, Harrison M, Lynd LD, Regier DA. Pollard S, et al. Among authors: weymann d. Eur J Hum Genet. 2021 Oct;29(10):1491-1501. doi: 10.1038/s41431-021-00882-1. Epub 2021 Apr 26. Eur J Hum Genet. 2021. PMID: 33903739 Free PMC article.
Correction to: Toward the diagnosis of rare childhood genetic diseases: what do parents value most?
Pollard S, Weymann D, Dunne J, Mayanloo F, Buckell J, Buchanan J, Wordsworth S, Friedman JM, Stockler-Ipsiroglu S, Dragojlovic N, Elliott AM, Harrison M, Lynd LD, Regier DA. Pollard S, et al. Among authors: weymann d. Eur J Hum Genet. 2021 Oct;29(10):1589. doi: 10.1038/s41431-021-00925-7. Eur J Hum Genet. 2021. PMID: 34145384 Free PMC article. No abstract available.
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.
Pleasance E, Titmuss E, Williamson L, Kwan H, Culibrk L, Zhao EY, Dixon K, Fan K, Bowlby R, Jones MR, Shen Y, Grewal JK, Ashkani J, Wee K, Grisdale CJ, Thibodeau ML, Bozoky Z, Pearson H, Majounie E, Vira T, Shenwai R, Mungall KL, Chuah E, Davies A, Warren M, Reisle C, Bonakdar M, Taylor GA, Csizmok V, Chan SK, Zong Z, Bilobram S, Muhammadzadeh A, D'Souza D, Corbett RD, MacMillan D, Carreira M, Choo C, Bleile D, Sadeghi S, Zhang W, Wong T, Cheng D, Brown SD, Holt RA, Moore RA, Mungall AJ, Zhao Y, Nelson J, Fok A, Ma Y, Lee MKC, Lavoie JM, Mendis S, Karasinska JM, Deol B, Fisic A, Schaeffer DF, Yip S, Schrader K, Regier DA, Weymann D, Chia S, Gelmon K, Tinker A, Sun S, Lim H, Renouf DJ, Laskin J, Jones SJM, Marra MA. Pleasance E, et al. Among authors: weymann d. Nat Cancer. 2020 Apr;1(4):452-468. doi: 10.1038/s43018-020-0050-6. Epub 2020 Apr 13. Nat Cancer. 2020. PMID: 35121966
29 results